Eculizumab, a monoclonal antibody against complement C5, transformed PNH treatment by blocking terminal complement activation and intravascular hemolysis, improving hemoglobin (Hb), and reducing transfusion needs and thrombosis (3, 4). Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.